Italy-based Advent has announced it has manufactured 13,000 doses of the University of Oxford’s investigational vaccine, ChAdOx1 nCoV-19, for use in the Phase II/III trial. To date, 4,000 doses have been delivered to the study researchers.

This supply deal was first signed between Advent and the University of Oxford’s Jenner Institute in February. Advent only received the first seed stock in late April.

Jenner Institute’s Professor Sarah Gilbert commented: “Speed is of the essence when facing a new outbreak such as this unprecedented Covid-19 pandemic.

“Advent has manufactured and delivered the vaccine very quickly, producing a clinical batch in just over one month since we provided the seed stock, enabling us to rapidly prepare for larger scale clinical trials.”